Diagnosis, management, and treatment of Alzheimer disease

A guide for the internist

Stephanie S. Richards, Hugh Hendrie

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

Alzheimer disease (AD) is a diagnosis of inclusion based on patient history, physical examination, neuropsychological testing, and laboratory studies; however, there is no definitive diagnostic test for AD. Early recognition of AD allows time to plan for the future and to treat patients before marked deterioration occurs. Effective treatment requires monitoring of symptoms, functional impairment, and safety, and the use of multiple treatment modalities including pharmacotherapy, behavioral management, psychotherapies, psychosocial treatments, and support and education for families. Pharmacotherapeutic agents available for AD only provide symptomatic relief. The cholinesterase inhibitors, tacrine and donepezil, are effective in improving cognition, delaying nursing home placement, and improving behavioral complications in some patients. Other cholinesterase inhibitors are in development, as are other cholinomimetic agents such as muscarinic and nicotinic receptor agonists. Symptomatic treatments are available for the psychiatric manifestations of AD. Anti-inflammatories, antioxidants, neurotrophic factors, and other agents are promising new treatments for the future.

Original languageEnglish
Pages (from-to)789-798
Number of pages10
JournalArchives of Internal Medicine
Volume159
Issue number8
DOIs
StatePublished - Apr 26 1999

Fingerprint

Alzheimer Disease
Cholinesterase Inhibitors
Nicotinic Agonists
Therapeutics
Tacrine
Nerve Growth Factors
Nicotinic Receptors
Muscarinic Receptors
Nursing Homes
Routine Diagnostic Tests
Psychotherapy
Cognition
Cholinergic Agents
Physical Examination
Psychiatry
Anti-Inflammatory Agents
Antioxidants
Safety
Education
Drug Therapy

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Diagnosis, management, and treatment of Alzheimer disease : A guide for the internist. / Richards, Stephanie S.; Hendrie, Hugh.

In: Archives of Internal Medicine, Vol. 159, No. 8, 26.04.1999, p. 789-798.

Research output: Contribution to journalArticle

@article{4cc430ef6c914b6cbe5417164fd04987,
title = "Diagnosis, management, and treatment of Alzheimer disease: A guide for the internist",
abstract = "Alzheimer disease (AD) is a diagnosis of inclusion based on patient history, physical examination, neuropsychological testing, and laboratory studies; however, there is no definitive diagnostic test for AD. Early recognition of AD allows time to plan for the future and to treat patients before marked deterioration occurs. Effective treatment requires monitoring of symptoms, functional impairment, and safety, and the use of multiple treatment modalities including pharmacotherapy, behavioral management, psychotherapies, psychosocial treatments, and support and education for families. Pharmacotherapeutic agents available for AD only provide symptomatic relief. The cholinesterase inhibitors, tacrine and donepezil, are effective in improving cognition, delaying nursing home placement, and improving behavioral complications in some patients. Other cholinesterase inhibitors are in development, as are other cholinomimetic agents such as muscarinic and nicotinic receptor agonists. Symptomatic treatments are available for the psychiatric manifestations of AD. Anti-inflammatories, antioxidants, neurotrophic factors, and other agents are promising new treatments for the future.",
author = "Richards, {Stephanie S.} and Hugh Hendrie",
year = "1999",
month = "4",
day = "26",
doi = "10.1001/archinte.159.8.789",
language = "English",
volume = "159",
pages = "789--798",
journal = "JAMA Internal Medicine",
issn = "2168-6106",
publisher = "American Medical Association",
number = "8",

}

TY - JOUR

T1 - Diagnosis, management, and treatment of Alzheimer disease

T2 - A guide for the internist

AU - Richards, Stephanie S.

AU - Hendrie, Hugh

PY - 1999/4/26

Y1 - 1999/4/26

N2 - Alzheimer disease (AD) is a diagnosis of inclusion based on patient history, physical examination, neuropsychological testing, and laboratory studies; however, there is no definitive diagnostic test for AD. Early recognition of AD allows time to plan for the future and to treat patients before marked deterioration occurs. Effective treatment requires monitoring of symptoms, functional impairment, and safety, and the use of multiple treatment modalities including pharmacotherapy, behavioral management, psychotherapies, psychosocial treatments, and support and education for families. Pharmacotherapeutic agents available for AD only provide symptomatic relief. The cholinesterase inhibitors, tacrine and donepezil, are effective in improving cognition, delaying nursing home placement, and improving behavioral complications in some patients. Other cholinesterase inhibitors are in development, as are other cholinomimetic agents such as muscarinic and nicotinic receptor agonists. Symptomatic treatments are available for the psychiatric manifestations of AD. Anti-inflammatories, antioxidants, neurotrophic factors, and other agents are promising new treatments for the future.

AB - Alzheimer disease (AD) is a diagnosis of inclusion based on patient history, physical examination, neuropsychological testing, and laboratory studies; however, there is no definitive diagnostic test for AD. Early recognition of AD allows time to plan for the future and to treat patients before marked deterioration occurs. Effective treatment requires monitoring of symptoms, functional impairment, and safety, and the use of multiple treatment modalities including pharmacotherapy, behavioral management, psychotherapies, psychosocial treatments, and support and education for families. Pharmacotherapeutic agents available for AD only provide symptomatic relief. The cholinesterase inhibitors, tacrine and donepezil, are effective in improving cognition, delaying nursing home placement, and improving behavioral complications in some patients. Other cholinesterase inhibitors are in development, as are other cholinomimetic agents such as muscarinic and nicotinic receptor agonists. Symptomatic treatments are available for the psychiatric manifestations of AD. Anti-inflammatories, antioxidants, neurotrophic factors, and other agents are promising new treatments for the future.

UR - http://www.scopus.com/inward/record.url?scp=0033606125&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033606125&partnerID=8YFLogxK

U2 - 10.1001/archinte.159.8.789

DO - 10.1001/archinte.159.8.789

M3 - Article

VL - 159

SP - 789

EP - 798

JO - JAMA Internal Medicine

JF - JAMA Internal Medicine

SN - 2168-6106

IS - 8

ER -